Enzymatica’s CEO comments on promising in-vitro data for ColdZyme
Enzymatica presents positive results from an in-vitro study at Medical University of Innsbruck. The results show that ColdZyme breaks the viral infection cycle and significantly reduces the viral load in human cells infected with influenza A. Enzymatica’s CEO Claus Egstrand visited BioStock’s studio to talk about ColdZyme and the study results.
Watch the interview with Enzymatica’s CEO Claus Egstrand below.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.
